United Kingdom (UK)
Recombinant monoclonal antibody to CD70. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma 6F9.
UniProt Accession Number of Target Protein: P32970
Alternative Name(s) of Target: TNFSF7; CD27L; CD27-L; CD27LG; CD27 ligand; CD70 antigen; Tumor necrosis factor ligand superfamily member 7
Immunogen: The original antibody was generated by immunizing BALB/c mice with recombinant human CD70-mFc fusion protein as immunogen.
Specificity: This antibody binds human and cynomolgus monkey CD70, a cytokine belonging to the tumor necrosis factor (TNF) ligand family, which acts as a ligand for TNFRSF27/CD27. It is a surface antigen present on activated T and B cells. The CD70-CD27 pathway plays an important role in the generation and maintenance of T cell immunity, in particular during antiviral responses. Upon CD27 binding, induces the proliferation of costimulated T-cells and enhances the generation of cytolytic T-cells. This cytokine is also reported to play a role in regulating B-cell activation, cytotoxic function of natural killer cells, and immunoglobulin synthesis. CD70 is also identified as an emerging target in cancer immunotherapy.
Application Notes: The binding this antibody to recombinant human CD70 was determined using ELISA. This antibody can positively react with human and cynomolgus monkey CD70 expressed on the surface of 786-0 renal carcinoma cells and CHO-K1-cmCD70 cells in a flow cytometric assay (CN110699327).
Antibody first published in: PMID: